Interleukin-16 promotes cardiac fibrosis and myocardial stiffening in heart failure with preserved ejection fraction

• Published in: PloS one 2013-07, Vol.8 (7), p.e68893-e68893
• Main Authors: Tamaki, Shunsuke, Mano, Toshiaki, Sakata, Yasushi, Ohtani, Tomohito, Takeda, Yasuharu, Kamimura, Daisuke, Omori, Yosuke, Tsukamoto, Yasumasa, Ikeya, Yukitoshi, Kawai, Mari, Kumanogoh, Atsushi, Hagihara, Keisuke, Ishii, Ryohei, Higashimori, Mitsuru, Kaneko, Makoto, Hasuwa, Hidetoshi, Miwa, Takeshi, Yamamoto, Kazuhiro, Komuro, Issei
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Allergies; Angiotensin; Angiotensin II; Angiotensins; Animals; Biology; Blood pressure; Cytokines; Diabetes; Diastolic pressure; Disease Models, Animal; Enzyme-linked immunosorbent assay; Female; Fibrosis; Genetic engineering; Genomes; Heart; Heart diseases; Heart failure; Heart Failure - diagnosis; Heart Failure - etiology; Heart Failure - pathology; Heart Failure - physiopathology; Hemodynamics; Hospitals; Humans; Hypertension; Hypertension - complications; Identification methods; Immune system; Infectious diseases; Infiltration; Inflammation; Interleukin; Interleukin 16; Interleukin-16 - blood; Interleukin-16 - genetics; Interleukin-16 - metabolism; Interleukins; Laboratory animals; Lasers; Lungs; Macrophages; Macrophages - metabolism; Macrophages - pathology; Male; Mathematics; Mechanical engineering; Medicine; Mice; Mice, Transgenic; Middle Aged; Multiplexing; Myocardium - metabolism; Myocardium - pathology; Patients; Prognosis; Quarks; Rats; Rheumatic diseases; Risk Factors; Rodents; Stiffening; Stiffness; Stroke Volume - genetics; Studies; Transgenic mice; Transplants & implants; University graduates; Ventricle; Ventricular Dysfunction, Left - etiology; Ventricular Dysfunction, Left - metabolism; Ventricular Dysfunction, Left - physiopathology
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0068893

Chronic heart failure (CHF) with preserved left ventricular (LV) ejection fraction (HFpEF) is observed in half of all patients with CHF and carries the same poor prognosis as CHF with reduced LV ejection fraction (HFrEF). In contrast to HFrEF, there is no established therapy for HFpEF. Chronic inflammation contributes to cardiac fibrosis, a crucial factor in HFpEF; however, inflammatory mechanisms and mediators involved in the development of HFpEF remain unclear. Therefore, we sought to identify novel inflammatory mediators involved in this process. An analysis by multiplex-bead array assay revealed that serum interleukin-16 (IL-16) levels were specifically elevated in patients with HFpEF compared with HFrEF and controls. This was confirmed by enzyme-linked immunosorbent assay in HFpEF patients and controls, and serum IL-16 levels showed a significant association with indices of LV diastolic dysfunction. Serum IL-16 levels were also elevated in a rat model of HFpEF and positively correlated with LV end-diastolic pressure, lung weight and LV myocardial stiffness constant. The cardiac expression of IL-16 was upregulated in the HFpEF rat model. Enhanced cardiac expression of IL-16 in transgenic mice induced cardiac fibrosis and LV myocardial stiffening accompanied by increased macrophage infiltration. Treatment with anti-IL-16 neutralizing antibody ameliorated cardiac fibrosis in the mouse model of angiotensin II-induced hypertension. Our data indicate that IL-16 is a mediator of LV myocardial fibrosis and stiffening in HFpEF, and that the blockade of IL-16 could be a possible therapeutic option for HFpEF.